Clinical trial
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With…
NCT00446082 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00446082 |
|---|---|
| Title | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease |
| Official title | A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoid Tumor, Acromegaly |
| Intervention type | Drug |
| Interventions | Pasireotide |
| Enrollment | 85 |
| Start date | Jun 1, 2006 |
| Primary completion | Nov 1, 2013 |
| Completion | Nov 1, 2013 |
| First posted | Mar 12, 2007 |
| Last update posted | Dec 21, 2020 |
| Countries | Belgium, Canada, Germany, Netherlands, Norway, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: